Abstract 2186
Background
Alpha-fetoprotein-producing gastric cancer (AFPGC) poses a therapeutic challenge worldwide because of its poor prognosis. This study aimed to systematically evaluate the efficacy and safety of apatinib targeted therapy in advanced AFPGC and investigate the predictive factors of apatinib treatment.
Methods
Three hundred thirty-seven patients were enrolled in the clinical trial AHEAD-G202, an open-label, prospective, multicenter, non-interventional study of apatinib for advanced metastatic gastric cancer. Among them, we recruited all the patients identified with AFPGC for this study. The clinical features, efficacy, adverse events, and survival were assessed.
Results
We enrolled 21 patients with AFPGC into this study. The objective response rate (ORR) of apatinib in patients with AFPGC was 10%, whereas the disease control rate (DCR) was 70%. The median progression-free survival (PFS) was 3.5 months [95%confidence interval (CI): 2.34-4.66]. The median overall survival (OS) was 4.5 months (95%CI: 3.49-5.51). The common grade adverse events (AEs) were hypertension (33.3%), fatigue (23.8%), and myelosuppression (19.0%). The most common grade 3 to 4 AEs were hypertension (4.8%), hand-foot syndrome (4.8%), anorexia (4.8%), and vomiting and nausea (4.8%). Carcinoembryonic antigen (CEA) elevation was considered to be a potential independent predictive factor (P = 0.030).
Conclusions
Apatinib showed promising efficacy and an acceptable safety profile in patients with advanced AFPGC. Antiangiogenic therapy may be a good strategy for the treatment of AFPGC.
Clinical trial identification
AHEAD-G202 (NCT02668380).
Editorial acknowledgement
Elsevier Language Editing Services.
Legal entity responsible for the study
The author.
Funding
Jiangsu HengRui Medcine Co., Ltd.; 2016 PUMCH Science Fund for Junior Faculty (Pumch-2016-1.13); Chinese Anti-cancer Association (CORP-143-09).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5747 - The routine use of sentinel lymph node biopsy in high risk DCIS lesions is not justified
Presenter: Fanny Preat
Session: Poster Display session 2
Resources:
Abstract
1837 - Oncological impact of re-excision for positive margin status after breast conserving surgery in invasive breast cancer
Presenter: Kenjiro Jimbo
Session: Poster Display session 2
Resources:
Abstract
4347 - Pneumonitis and fibrosis after breast cancer radiation.
Presenter: Jarle Karlsen
Session: Poster Display session 2
Resources:
Abstract
2280 - Prognosis of mastectomy with reconstruction after neoadjuvant chemotherapy: a nationwide study in Korean Breast Cancer Society
Presenter: Sungmin Park
Session: Poster Display session 2
Resources:
Abstract
804 - A negative prognosis of radiotherapy-induced lower lymphocyte to monocyte ratio in patients with breast cancer
Presenter: Chang-ik Yoon
Session: Poster Display session 2
Resources:
Abstract
2701 - Patient data to monitor clinical patterns in early and advanced breast cancer in Europe
Presenter: Francesco Giusti
Session: Poster Display session 2
Resources:
Abstract
1437 - A critical appraisal of quality indicators of breast cancer treatment in Belgium
Presenter: Didier Verhoeven
Session: Poster Display session 2
Resources:
Abstract
1534 - Predictors of adherence among post-menopausal women receiving adjuvant endocrine therapy for breast cancer in Ontario, Canada
Presenter: Phillip Blanchette
Session: Poster Display session 2
Resources:
Abstract
4363 - Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study
Presenter: Emilia Montagna
Session: Poster Display session 2
Resources:
Abstract
2679 - Baseline Quality of life (QoL) and chemotherapy related toxicities (CRT) in localized breast cancer (BC) patients (pts): the French multicentric prospective CANTO cohort study
Presenter: Idlir Licaj
Session: Poster Display session 2
Resources:
Abstract